

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date November 16, 2012

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

1. **Call to Order – Chair Richard Brodsky, MD** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners** (See guidelines on page 2)

The Department's method for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are new classes or classes where ****new information exists and public testimony will be taken.** Public testimony will be taken for classes shown in **Blue** will only if ****new information is received.** Classes shown in **Green**, no significant changes have been noted and no public testimony will be taken.

****New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.**

4. Public comment , discussion & vote on **Red Classes**

Tab 1: Anticonvulsants, Oral (1 st and 2 nd Generation) – Re-review	Tab 2: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) *Previously COX-2 Inhibitors* - Review/Re-review
---	---

5. Public comment, discussion & vote **Blue Classes**

Tab 3: Sedative/Hypnotics – Re-review	Tab 4: Long-Acting Narcotic Analgesics – Re-Review
Tab 5: Restless Leg Syndrome Agents (*Dopamine Agonists only – Antiparkinsons Agents Packet) – Re-review	

6. Discussion & vote on **Green Classes**

Tab 6: Atypical (2 nd Generation) Antipsychotics – Re-review	Tab 6: Long Acting Injectable Atypical (2 nd Generation) Antipsychotics – Re-Review
Tab 7: Stimulants and Related Agents – Re-review	Tab 8: Progestins for Cachexia – Re-review
Tab 9: Antidepressants, Other – Re-review	Tab 10: Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) – Re-review
Tab 11: Bladder Relaxant Preparations – Re-review	Tab 12: Opiate Dependence Treatments – Re-review
Tab 13: Short-Acting Narcotic Analgesics – Re-review	Tab 14: Skeletal Muscle Relaxants – Re-review
Tab 15: Topical Steroids, Low Potency – Re-review	Tab 15: Topical Steroids, Medium Potency – Re-review
Tab 15: Topical Steroids, High Potency – Re-review	Tab 15: Topical Steroids, Very High Potency – Re-review
Tab 16: Growth Hormone – Re-review	

7. **Break as needed** – 15 minutes
8. **Review minutes from September 21, 2012 meeting**
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Next Meeting Date: January 18, 2013

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting. Medicaid providers or other individuals providing public comment without affiliations to a manufacturer do not need to register prior to the meeting and comments will be taken during the public comment period after the roll call.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted Magellen prior to the meeting.